ATyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
ATyr Pharma to Participate in RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
SAN DIEGO, Oct. 04, 2022 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview as part of the RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium, which is scheduled to take place virtually on Friday, October 7, 2022.
聖迭戈，2022年10月4日(環球網)--納斯達克公司(ATyr Pharma，Inc.)是一家利用其專利tRNA合成酶平臺發現和開發一流藥物的生物治療公司，該公司今天宣佈，Sanjay S.Shukla，M.D.，M.S.和首席執行官總裁和首席執行官將在定於2022年10月7日(星期五)舉行的加拿大皇家銀行生物技術專家洞察：肺/肺疾病小型研討會上介紹公司概況。
Details of the presentation appear below:
演示文稿的詳細信息如下：
Event: RBC Biotech Expert Insights: Pulmonary/Lung Disease Mini-Symposium
Date: Friday, October 7, 2022
Time: 11:00am ET / 8:00am PT
Webcast Link:
活動：RBC生物技術專家洞察：肺/肺疾病小型研討會
日期：2022年10月7日(星期五)
時間：東部時間上午11：00/太平洋時間上午8：00
網絡直播鏈接：
The Mini-Symposium will include a series of company presentations and Key Opinion Leader (KOL) sessions in the area of pulmonary/lung disease. Planned KOL interviews include physician experts in pulmonary sarcoidosis and systemic sclerosis (SSc, also known as scleroderma)-associated interstitial lung disease, among other disease indications.
小型研討會將包括一系列關於肺/肺部疾病領域的公司介紹和關鍵意見領袖(KOL)會議。計劃中的KOL訪談包括肺結節病和系統性硬化症(SSC，也稱為硬皮病)相關間質性肺部疾病等疾病適應症的內科專家。
To attend aTyr's company presentation, register at the link above. To attend the KOL sessions, investors may contact their RBC sales representative to register. Following the event, a replay of the aTyr company presentation will be available on the Investor's section of the company's website at for at least 90 days.
要參加aTyr的公司説明會，請點擊上面的鏈接註冊。要參加KOL會議，投資者可以聯繫他們的加拿大皇家銀行銷售代表進行註冊。活動結束後，aTyr公司介紹的重播將在該公司網站的投資者部分進行，至少90天。
About aTyr
ABOUT aTyr
aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr's research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr's primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. For more information, please visit
ATyr是一家生物治療公司，利用其專有的tRNA合成酶平臺從事一流藥物的發現和開發。ATyr的研究和開發工作集中在一個新發現的生物學領域，即tRNA合成酶的細胞外功能和信號通路。ATyr已經建立了一個全球知識產權中心，針對來自20個tRNA合成酶基因及其細胞外靶標的潛在蛋白質成分管道。ATyr的主要關注點是efzofitimod，這是一種臨牀階段的候選產品，它與神經匹林-2受體結合，旨在下調纖維化肺部疾病的免疫參與。欲瞭解更多信息，請訪問
Contact:
Ashlee Dunston
Director, Investor Relations and Corporate Communications
adunston@atyrpharma.com
聯繫方式：
阿什莉·鄧斯頓
董事、投資者關係和企業傳播
郵箱：adunston@atyrpharma.com